ArticleHealth science reports2026
Comparison of Efficacy of Suprachoroidal Triamcinolone Acetonide Alone or in Combination With Intravitreal Bevacizumab for Treatment of Diabetic Macular Edema: A Prospective Comparative Study.
Article in Health science reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: This study was designed to evaluate the safety, efficacy, and durability of suprachoroidal triamcinolone acetonide, administered either alone or in combination with intravitreal bevacizumab (IVB), in the treatment of diabetic macular edema (DME). Methods: This prospective comparative interventional study was conducted in the Ophthalmology Department at Mayo Hospital, Lahore, from May 2020 to March 2021. Sixty patients with DME were enrolled after obtaining informed consent. Baseline assessments included best-corrected visual acuity (BCVA), intraocular pressure (IOP), a detailed fundus examination, and spectral-domain optical coherence tomography (SD-OCT) for measurement of central subfield thickness (CST). Participants were allocated into two groups. One group received a combination of 4 mg suprachoroidal triamcinolone acetonide and intravitreal bevacizumab, while the second group received 4 mg suprachoroidal triamcinolone acetonide alone. Patients were followed clinically and anatomically to assess treatment outcomes. Results: Both groups demonstrated statistically significant reductions in CST from baseline ( Conclusion: Suprachoroidal administration of 4 mg triamcinolone acetonide combined with intravitreal bevacizumab is more effective than triamcinolone monotherapy in reducing central subfield thickness and improving visual acuity in patients with DME. The combination approach provides superior anatomical and functional outcomes, suggesting a synergistic therapeutic effect and representing a promising treatment strategy for DME.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.